Outcomes
REGRESSION, ADVERSE EVENT, CIN 1
Primary outcomes included histopathological regression to normal (complete response) or CIN 1 (partial response) at week 16 and IGMKK16E7 safety. Secondary outcomes included histopathological regression at week 24, immunological response, cytological regression, and viral clearance. All safety outcomes were based on adverse event reporting (see the Clinical Trial Protocol for criteria, see the 